We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

141 hedge funds and large institutions have $1.25B invested in Immunogen Inc in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 56 increasing their positions, 38 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

47% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 38

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

10% more funds holding

Funds holding: 128141 (+13)

4% more capital invested

Capital invested by funds: $1.2B → $1.25B (+$53.5M)

8% less call options, than puts

Call options by funds: $9.24M | Put options by funds: $10M

Holders
141
Holders Change
+13
Holders Change %
+10.16%
% of All Funds
4.57%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
23
Increased
56
Reduced
38
Closed
8
Calls
$9.24M
Puts
$10M
Net Calls
-$786K
Net Calls Change
-$5.34M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$217M +$1.32M +75,067 +0.6%
Primecap Management
2
Primecap Management
California
$214M +$1.66M +94,300 +0.8%
ClearBridge Investments
3
ClearBridge Investments
New York
$122M +$13.4M +762,780 +12%
Vanguard Group
4
Vanguard Group
Pennsylvania
$82.2M +$2.75M +156,166 +3%
SAM
5
Sectoral Asset Management
Quebec, Canada
$62.2M -$48.6M -2,766,091 -43%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$57.1M -$3M -170,675 -5%
BB
7
BB Biotech
Switzerland
$55.8M +$241K +13,722 +0.4%
BFA
8
BlackRock Fund Advisors
California
$53.6M +$7.12M +404,777 +15%
State Street
9
State Street
Massachusetts
$44.9M +$652K +37,074 +1%
Norges Bank
10
Norges Bank
Norway
$40.9M +$31.3M +1,781,777 +286%
BIT
11
BlackRock Institutional Trust
California
$39.8M -$1.37M -77,995 -3%
First Trust Advisors
12
First Trust Advisors
Illinois
$36.3M +$8.68M +493,972 +30%
AG
13
Artal Group
Luxembourg
$28.1M -$879K -50,000 -3%
Northern Trust
14
Northern Trust
Illinois
$20.5M -$136K -7,727 -0.6%
GIM
15
Granahan Investment Management
Massachusetts
$18.7M -$998K -56,770 -5%
PA
16
Pinnacle Associates
New York
$16M -$153K -8,722 -0.9%
Deutsche Bank
17
Deutsche Bank
Germany
$9.08M -$691K -39,331 -7%
Morgan Stanley
18
Morgan Stanley
New York
$7.88M +$253K +14,371 +3%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$7.4M +$221K +12,573 +3%
Wells Fargo
20
Wells Fargo
California
$7.2M +$525K +29,874 +8%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$6.95M +$696K +39,578 +11%
TCIM
22
TIAA CREF Investment Management
New York
$6.1M -$148K -8,437 -2%
BIM
23
BlackRock Investment Management
Delaware
$4.27M +$185K +10,545 +4%
GC
24
Guggenheim Capital
Illinois
$3.98M +$861K +48,971 +27%
Charles Schwab
25
Charles Schwab
California
$3.49M +$147K +8,382 +4%

IMGN Hedge Fund Activity: Q3 2013 in Review

141 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q3 2013, worth a combined $1.25B — up 4.5% from $1.2B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new IMGN positions and 8 closed out — a net gain of 15 holders — while 56 added to existing stakes and 38 trimmed.

The largest buyer was Norges Bank, adding an estimated $31.3M. The largest seller was Sectoral Asset Management, cutting an estimated $48.6M.

  • 141 institutional investors held Immunogen Inc (IMGN) as of Q3 2013, up from 128 in Q2 2013.
  • Funds reported $1.25B of Immunogen Inc stock for Q3 2013, up 4.5% quarter-over-quarter.
  • 23 funds opened new Immunogen Inc positions in Q3 2013 and 8 closed out, a net change of +15 holders.
  • The largest Immunogen Inc buyer in Q3 2013 was Norges Bank, an estimated $31.3M added.
  • The largest Immunogen Inc seller in Q3 2013 was Sectoral Asset Management, an estimated $48.6M sold.

Based on aggregated 13F filings for Q3 2013.